IntelliPharmaCeutics International Inc. (IPCI) EPS Estimated At $-0.05

March 15, 2018 - By Clifton Ray

 IntelliPharmaCeutics International Inc. (IPCI) EPS Estimated At $ 0.05

Analysts expect IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) to report $-0.05 EPS on April, 10.They anticipate $0.02 EPS change or 28.57 % from last quarter’s $-0.07 EPS. After having $-0.08 EPS previously, IntelliPharmaCeutics International Inc.’s analysts see -37.50 % EPS growth. The stock increased 15.77% or $0.088 during the last trading session, reaching $0.649. About 897,327 shares traded or 146.68% up from the average. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has risen 16.57% since March 15, 2017 and is uptrending. It has underperformed by 0.13% the S&P500.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering Intellipharmaceutics Intl (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Intellipharmaceutics Intl had 8 analyst reports since December 31, 2015 according to SRatingsIntel. On Monday, March 5 the stock rating was maintained by H.C. Wainwright with “Buy”. As per Friday, February 16, the company rating was downgraded by Maxim Group. As per Monday, February 12, the company rating was maintained by H.C. Wainwright. Maxim Group maintained the shares of IPCI in report on Tuesday, June 6 with “Buy” rating. The company was maintained on Friday, July 21 by Maxim Group. Maxim Group maintained IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) rating on Thursday, December 31. Maxim Group has “Buy” rating and $6.0 target. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) earned “Buy” rating by Maxim Group on Friday, June 30.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $22.51 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

More notable recent IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) news were published by: which released: “Intellipharmaceutics Reports on Launch of Additional Strengths of Generic …” on November 30, 2017, also with their article: “Form 6-K Intellipharmaceutics For: Mar 14” published on March 14, 2018, published: “Intellipharmaceutics (IPCI) Announces 5.83M Share Registered Direct Offering …” on March 14, 2018. More interesting news about IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) were released by: and their article: “Intellipharmaceutics Announces Closing of US$4 Million Financing” published on October 13, 2017 as well as‘s news article titled: “FDA declines to approve Intellipharma’s opioid painkiller” with publication date: September 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: